SSRIs

PreclinicalSmall molecule

Eli Lilly

SSRIs is one of 84 small molecule programs targeting Sexual Dysfunction. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sexual DysfunctionActive, not recruiting

Post-Traumatic Stress DisorderActive, not recruiting

Obsessive-Compulsive DisorderActive, not recruiting

Sexual DysfunctionPreclinical

Active, not recruiting

Post-Traumatic Stress DisorderPreclinical

Active, not recruiting

Obsessive-Compulsive DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

61 competitors in Post-Traumatic Stress Disorder

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Approved

5 2

Minipress

Pfizer

Approved

4 3

Epidiolex

Jazz Pharmaceuticals

Approved

2 4

Revia

Teva

Approved

1 5

Marinol

Jazz Pharmaceuticals

Approved

1 6

Ritalin

Novartis

Approved

1 7

Namenda

AbbVie

Approved

1 8

Zoloft

VViatris Specialty LLC

Approved

7 9

Inderal

WWyeth-Lederle Vaccines

Approved

5 10

Estrace

Novo Nordisk

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

N/ARecruiting

Obsessive-Compulsive Disorder

NCT02431845

Clinical

Trials by Indication[1]

Major Depressive Disorder6 trials

A Kynurenine Pathway-based Molecular Imaging Study of Individualized Diagnosis and Treatment for Major Depressive Disorder

Unknown status·SShanghai Mental Health Center··NCT04208932·440 enrolled

Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder

Active, not recruiting·AAsad Ullah Jan·N/A·NCT06957223·80 enrolled

Intradermal Needle Therapy for Major Depressive Disorder

Unknown status·TThe Third Affiliated hospital of Zhejiang Chinese Medical University·N/A·NCT05352113·120 enrolled

Show 3 more trials

Efficacy and Safety of Intradermal Acupuncture for Major Depressive Disorder

Unknown status·XXiaomei Shao·N/A·NCT05605002·90 enrolled

A Pilot Study on Effect of add-on Sulforaphane to SSRIs and Application of Niacin Skin Flush Response Test in Major Depressive Disorder

Unknown status·SShanghai Mental Health Center·Phase 4·NCT05148169·150 enrolled

Acupuncture Therapy Based on Biological Specificity of Acupoints for Major Depressive Disorder

Unknown status·TThe Third Affiliated hospital of Zhejiang Chinese Medical University·N/A·NCT05353543·120 enrolled

Obsessive-Compulsive Disorder2 trials

Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder

Recruiting·SSeverance Hospital·N/A·NCT02431845·200 enrolled

The Gut Microbiota in Obsessive-Compulsive Disorder

Completed·MMcMaster University·N/A·NCT02285699·43 enrolled

MDD1 trial

Objective Diagnostic Markers and Personalized Intervention in MDD Patients

Unknown status·PPeking University·N/A·NCT02023567·2,400 enrolled

Post-Traumatic Stress Disorder1 trial

Post-Traumatic Growth Following Eye Movement Desensitization and Reprocessing Therapy Versus SSRIs in Patients With Post-Traumatic Stress Disorder

Active, not recruiting·AAsad Ullah Jan·N/A·NCT06957210·130 enrolled

Sexual Dysfunction1 trial

Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months

Completed· Eli Lilly logo

Eli Lilly··NCT00561509·1,626 enrolled

2 more indications

Depression1 trial

Assessment of the Improvement in Cognitive Levels of Postmenopausal Depression Patients by Estrogen

Recruiting·XXiao Wang·N/A·NCT06358014·40 enrolled

Unspecified1 trial

A Multicentre Clinical Study

Not yet recruiting·ZZhongda Hospital··NCT07062666·2,250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for SSRIs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SSRIs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SSRIs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Eli Lilly

SSRIs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Major Depressive Disorder6 trials

Obsessive-Compulsive Disorder2 trials

MDD1 trial

Post-Traumatic Stress Disorder1 trial

Sexual Dysfunction1 trial

Depression1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News